Amplifying samples to boost sensitivity of UTI tests: BioAmp, USA

BioAmp Diagnostics is a startup company based in the San Francisco Bay area. 

BioAmp is developing a UTI test that detects biomarkers for antibiotic resistance, that uses a colour-changing, biochemistry-based approach. Its test detects the activity of resistance biomarkers, whose presence indicates the bacterium causing infection is resistant to typical first-line antibiotics that are used to treat patients. Its patented platform amplification technology overcomes the sensitivity limitations of other biochemical tests and enables direct testing on urine at point-of-care.

“Participating in the Longitude Prize has positively impacted our approach as it’s given us access to a variety of health care experts. receiving feedback from these experts has been really important to us developing a diagnostic that would fit the current clinical workflow, thus minimizing implementation and adoption barriers. Overall, this has given us a lot of confidence in our approach and in our product.” Dr Tara Deboer

BioAmp Diagnostics is composed of an interdisciplinary team of two technical founders and a group of business, medical, and scientific advisors. Its expertise covers microbiology, molecular biology, chemistry, immunology, diagnostics, and engineering.

Speakers in this video from the BioAmp team:

Dr Tara Deboer, Chief Executive Officer, BioAmp Diagnostics

Dr Angel Resendez, Director of Chemistry – Small Molecule Discovery, BioAmp Diagnostics

Isha Kane, Project Manager & Market Strategist, BioAmp Diagnostics